Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard
of care (SOC) chemotherapy with cisplatin and paclitaxel as neoadjuvant treatment in
participants with locally advanced esophageal squamous cell carcinoma (ESCC), and to explore
treatment resistance mechanisms.